Miramgul E. Dyneva

Miramgul E. Dyneva

Auto-generated profile, based on publicly available information

Miramgul E. Dyneva

Medical Center “Good Doctor”, Moscow, 107076, Russian Federation

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2019 in Acta Naturae
Verified
Journal Article
Open access
ISI. P. Shilovskiy
I. P. Shilovskiy
MDM. E. Dyneva
M. E. Dyneva
OKO. M. Kurbacheva
O. M. Kurbacheva
DKDmitry Kudlay
Dmitry Kudlay
MKM. R. Khaitov
M. R. Khaitov
Cytokines of the interleukin-1 (IL-1) family play an important role in the realization of the protective functions of innate immunity and are the key mediators involved in the pathogenesis of a wide range of diseases, including various manifestations of allergy. The IL-1 family includes more than 11 members. However, the functions of many of them remain to be elucidated. Recently, new members of the IL-1 family have been discovered. In 2000, several independent research groups reported the discovery of a new interleukin of this family, which was named IL-37, or IL-1F7 (according to the new nomenclature). IL-37 was assigned to the IL-1 family based on its structural similarity with other members of this family. The study of its biological properties showed that its activity changes in inflammatory diseases, such as rheumatoid arthritis, psoriasis, as well as allergic diseases (allergic rhinitis, bronchial asthma, and atopic dermatitis). However, unlike most members of the IL-1 family, IL-37 acts as a negative regulator of inflammation. Activation of IL-37 suppresses inflammation, resulting in the suppression of inflammatory cytokines and chemokines, which in turn prevents infiltration of pro-inflammatory cells, mainly eosinophils and neutrophils. The exact molecular and cellular mechanisms of the anti-inflammatory effect of IL-37 in the development of allergic diseases (AD) have not been fully studied. This review summarizes and analyzes the accumulated experimental data on the role of IL-37 in the pathogenesis of AD, such as allergic rhinitis, bronchial asthma, and atopic dermatitis.

1 January 2019 in Russian Bulletin of Otorhinolaryngology
Verified
Journal Article
Closed access
PDF file
ESE. L. Savlevich
E. L. Savlevich
OKO. M. Kurbacheva
O. M. Kurbacheva
VEV. I. Egorov
V. I. Egorov
MDM. E. Dyneva
M. E. Dyneva
ISI. P. Shilovskiy
I. P. Shilovskiy
MKM. R. Khaitov
M. R. Khaitov
Rhinosinusitis with nasal polyps (CRSwNP) is often followed by a range of comorbid states, influence of which on the course of the main pathology process remains insufficiently studied. To study the gene expression level of cytokines potentially talking part in the development of inflammation in nasal polyps with different phenotypes of CRSwNP. All the patients with CRSwNP were divided into 4 equal groups, 36 patients in each subgroup: group 1 - CRSwNP without comorbid pathology; group 2 - CRSwNP+atopy; group 3 - CRSwNP + non-allergic bronchial asthma (BA); control group 4 - 36 patients diagnosed with hypertrophic rhinitis without atopy and without bronchial asthma. Using the real-time polymerase chain reaction (Real-Time PCR) method, the study of expression level of mRNA genes coding proteins IL-1β, IL-4, IL-5, IL-13, IL-17F, IL-25, IFN-y, TSLP in polyp tissue was conducted. The statistically proved difference of expression level of cytokines depending on the CRSwNP phenotype was educed. If CRSwNP and atopy were combined, the gene expression level of all studied cytokines was statistically higher than that of CRSwNP without comorbid pathology; and the expression level of IL-17F, IL-25 and TSLP was more intense that in the group of CRSwNP + BA. There was no difference between the patients with comorbid allergy and comorbid BA regarding the gene expression of IFN-y, IL-5 and IL-13 cytokines. Among different phenotypes of CRSwNP no difference in IL-1β expression level was detected, which evidences of persisting inflammatory process, and the IL-4 gene expression level was lower than the detection level in all the groups. With different CRSwNP phenotypes different inflammatory patterns are detected, which indicates different character of the pathology process course among these groups of patients. Higher expression level of cytokine genes, which are a marker of epithelial damage of IL-25 and TSLP, is found only among the patients with CRSwNP and atopy. It suggests that forming of CRSwNP without comorbid pathology is connected with other pathologic mechanisms, not with the damage to epithelial barrier. If CRSwNP + BA and CRSwNP + atopy were combined, the expression level of IFN-y, IL-5, IL-13 and IL-17F genes was higher than the one in the group of patients with CRSwNP without comorbid pathology. In view of obtained data, all the patients with CRSwNP shall be screened for bronchial asthma and the allergy diagnostic shall be conducted.

19 February 2021 in PULMONOLOGIYA
Verified
Journal Article
Closed access
PDF file
OKO. M. Kurbacheva
O. M. Kurbacheva
MDM. E. Dyneva
M. E. Dyneva
ISIgor Shilovskiy
Igor Shilovskiy
ESE. L. Savlevich
E. L. Savlevich
VKV. I. Kovchina
V. I. Kovchina
MKM. R. Khaitov
M. R. Khaitov
The combination of bronchial asthma (BA) and chronic rhinosinusitis with nasal polyps (CRSwNP) is currently considered a separate phenotype wit1 dysregulation of pro- and anti-inflammatory cytokines as one of t1e leading causes of inflammation.The aimof this study was to investigate the local and systemic inflammatory process in patients with BA associated with CRSwNP.Methods. The study enrolled 96 volunteers divided into 4 groups: the 1stwas healthy control (Normal); the 2ndhad allergic BA associated with CRSwNP; the 3rdhad nonallergic BA associated with CRSwNP; the 4thhad CRSwNP without BA. All participants of the study underwent clinical, laboratory, instrumental, and histological examinations. The expression ofil-1β, il-4, il-,5 il-6, il-13, il-37, il-17f, ifn-γ, tnf-αandtgf-βgenes was assessed in the peripheral blood mononuclear cells - PBMC and in the polyp tissue using RT-PCR. We also estimated the expression oftslp, il-25andil-33in the polyp tissue and expression of GATA3 and RORgt transcription factors in PBMC.Results. The pathogenesis of BA associated with CRSwNP is characterized by the dys-regulation of the local pro- and anti-inflammatory cytokines of the Th1-, Th2-, Th17- immune response. Moreover, the high expression ofil-37gene in patients with BA associated with CRSwNP, and especially in patients with not-allergic BA associated with CRSwNP, probably indicates the «inclusion» of the compensatory mechanism. In addition, BA associated with CRSwNP is characterized by severe course of both diseases. A nonallergic BA associated with CRSwNP is characterized by more pronounced eosinophilic inflammation, which is an unfavorable prognostic factor.Conclusion. Thus, a comparison of the levels of local and systemic cytokine expression in patients with BA associated with CRSwNP led to the conclusion that CRSwNP affects the local immunity more than systemic immunity. However, the latter is affected to some extent in the long-term as well.

30 October 2021 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
ОКО. М. Курбачева
О. М. Курбачева
МДМ. Е. Дынева
М. Е. Дынева
НИН. И. Ильина
Н. И. Ильина
The asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), atopic dermatitis (AD), eosinophilic esophagitis and other diseases based on T2-inflammation are a widespread in the world. It has led to the development of genetically engineered drugs aimed at individual and specific components of inflammation. One of the leading positions in the pathogenesis of T2-mediated diseases is occupied by interleukin (IL)-4 and IL-13, which explains the prospects of studying these cytokines for the creation of anti-IL-4/IL-13 monoclonal antibodies. The first immunobiological drug was registered to directe against the α subunit of the IL-4 receptor (IL-4Ra), common to both IL-4 and IL-4/IL-13 receptor complexes is dupilumab which is a fully human monoclonal antibody. Dupilumab targets the IL-4 receptor alpha chain (IL-4Rα), common to both IL-4R complexes: type 1 (IL-4Rα/γc; IL-4 specific) and type 2 (IL-4Rα/IL-13Rα1; IL-4 and IL-13 specific). Because the IL-4/IL-13/STAT6 signaling pathway plays a significant role in T2 inflammation. IL-4 and IL-13 are secreted by several cells and, along with other T2 cytokines, as well as with the participation of IL-33, IL-25 and TSLP can stimulate cells to further secrete pro-inflammatory cytokines, contributing to the maintenance of the inflammatory process. Currently, dupilumab has been studied in at least 3,000 patients with asthma, AD, CRSwNP and eosinophilic esophagitis. The results of investigation show an acceptable safety profile in placebo-controlled studies worldwide. In this article, we have highlighted the results of numerous clinical studies and observations that have proven the effectiveness and safety of the use of dupilumab in asthma, AD, CRSwNP, prurigo, eosinophilic esophagitis and eosinophilic pneumonia.

15 March 2021 in Russian Journal of Allergy
Verified
Journal Article
Open access
MDMiramgul E. Dyneva
Miramgul E. Dyneva
GAGulyumkhan E. Aminova
Gulyumkhan E. Aminova
OKOksana Kurbacheva
Oksana Kurbacheva
NINatalya I. Il'Ina
Natalya I. Il'Ina
Airway inflammation plays a crucial role in the development of asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). The severity of inflammation influences the clinical picture of the disease and, most importantly, the effectiveness of therapy. To date, the growth in the incidence rate of asthma and CRSwNP is still high and the effectiveness of existing therapy for severe asthma, especially associated with CRSwNP, is unsatisfactory. Therefore, the aim is to investigate novel diagnostic tools and therapies. The emergence of biologics that target specific inflammatory pathways is a promising step forward to achieve control of severe uncontrolled asthma and recurrent CRSwNP. Dupilumab is one of recently introduced monoclonal antibodies, which has shown significant advances in the treatment of asthma and CRSwNP. Dupilumab is a fully human monoclonal antibody targeted to interleukin-4 receptor alpha subunit (IL-4R) that is a receptor for both IL-4 and IL-13. Thus, it helps to inhibit cytokine T2-signaling (IL-4 and IL-13), since the IL-4/IL-13/STAT6 signaling pathway plays a crucial role in T2-inflammation. In Russia, dupilumab is currently approved as a treatment for atopic dermatitis (in children over 6 years of age), asthma (in children over 12 years of age) and severe CRSwNP in adults. This article summarizes the main data on dupilumab and its efficacy in patients with asthma and CRSwNP and presents a relevant case report.

1 January 2023 in Immunologiya
Verified
Journal Article
Open access
ESE.L. Savlevich
E.L. Savlevich
EME.S. Mitrofanova
E.S. Mitrofanova
OKO.M. Kurbacheva
O.M. Kurbacheva
MDM.E. Dyneva
M.E. Dyneva
ISIgor Shilovskiy
Igor Shilovskiy
MKM.R. Khaitov
M.R. Khaitov
Роль металлопротеиназ в процессе ремоделирования слизистой оболочки околоносовых пазух при хроническом риносинусите